Data as of Sep 17
| +0.14 / +1.02%|
The 8 analysts offering 12-month price forecasts for Durata Therapeutics Inc have a median target of 22.50, with a high estimate of 26.00 and a low estimate of 12.00. The median estimate represents a +61.64% increase from the last price of 13.92.
The current consensus among 9 polled investment analysts is to Buy stock in Durata Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.